Horizon Europe

Debate between Baroness Warwick of Undercliffe and Viscount Camrose

Wednesday 13th September 2023 Lords Chamber

[Viscount Camrose (Con)]

I am very happy to agree. The work done collectively across all programmes in the last Horizon cut across 163 countries and created 237,000 collaborative links—although quite what that means I am not sure. To me, it paints a picture of a global, highly collaborative, shared investigative approach to probing the great scientific problems of our time.

[Baroness Warwick of Undercliffe (Lab)]

My Lords, there is clearly overwhelming relief from the academic community that we have at last rejoined, although I echo my noble friend’s point that there is a lot of ground to make up and a lot of good will and partnerships to be rebuilt. I will ask some practical questions of the Minister. What happens to researchers who have already been funded through the guarantee? Can they be transferred back into Horizon? What will happen to the underspend created by UKRI’s guarantee? Will it be reinvested in UK R&D before association takes place?

[Viscount Camrose (Con)]

I thank the noble Baroness for the question. Any open calls now are for programme 24 or are outstanding for programme 23. Those calls will be dedicated to each programme. Those for programme 23—there are not very many left—are covered by the Horizon guarantee scheme or programme 24, in which we now participate. All of the underspend will go to our commitment to spend £20 billion a year on R&D by 2024-25, and exactly how we take full advantage of that will be the subject of future announcements.

Medical Research Charities

Debate between Baroness Warwick of Undercliffe and Viscount Camrose

Wednesday 21st June 2023 Lords Chamber

[The Parliamentary Under-Secretary of State, Department for Science, Innovation and Technology (Viscount Camrose) (Con)]

We are moving forward with discussions on the UK’s involvement in Horizon Europe; that is our preference. We will continue to engage with representatives across the sector, including medical research charities, as these discussions progress. We have engaged widely with the sector on association and Pioneer, including with medical research charities, and we continue to welcome thoughts on the proposals laid out in the Pioneer prospectus.

[Baroness Warwick of Undercliffe (Lab)]

I thank the Minister for that reply, and I am pleased that he recognises the vital contribution made by charity-funded medical research to the UK’s excellent R&D reputation. I am grateful for the briefings we have had from various charities, including the British Heart Foundation, which have all reinforced that. They point out the huge progress that has been made—for example, in cardiovascular research—in the past few years, which has been made possible because of the collaboration and recruitment of scientists, technicians and researchers, both within Europe and around the world. However, it is clear that there is still uncertainty about the degree to which the Government are communicating with or are at least involving those charities in the work they are doing and the negotiations. Surely the Minister accepts that it would be sensible—indeed, essential—for them to have a seat at the table in the negotiations and in looking at the opportunities available from both programmes.

[Viscount Camrose (Con)]

DSIT meets medical research charities on a quarterly basis through the DSIT charities forum. That brings together government representatives with a broad range of member charities from the Association of Medical Research Charities—AMRC—including the British Heart Foundation and Cancer Research UK, as well as smaller charities for topic-specific discussions, which includes the Horizon or Pioneer programmes. In addition, DSIT meets policy officials from AMRC on a monthly basis.